Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure

Delia Blaya, Elisa Pose, Mar Coll, Juan José Lozano, Isabel Graupera, Robert Schierwagen, Christian Jansen, Pedro Castro, Sara Fernandez, Julia Sidorova, Mariuca Vasa-Nicotera, Elsa Solà, Joan Caballería, Jonel Trebicka, Pere Ginès, Pau Sancho-Bru*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

10 Downloads (Pure)

Abstract

Background & Aims: MicroRNAs (miRNAs) circulate in several body fluids and can be useful biomarkers. The aim of this study was to identify blood-circulating miRNAs associated with cirrhosis progression and acute-on-chronic liver failure (ACLF). Methods: Using high-throughput screening of 754 miRNAs, serum samples from 45 patients with compensated cirrhosis, decompensated cirrhosis, or ACLF were compared with those from healthy individuals (n = 15). miRNA levels were correlated with clinical parameters, organ failure, and disease progression and outcome. Dysregulated miRNAs were evaluated in portal and hepatic vein samples (n = 33), liver tissues (n = 17), and peripheral blood mononuclear cells (PBMCs) (n = 16). Results: miRNA screening analysis revealed that circulating miRNAs are dysregulated in cirrhosis progression, with 51 miRNAs being differentially expressed among all groups of patients. Unsupervised clustering and principal component analysis indicated that the main differences in miRNA expression occurred at decompensation, showing similar levels in patients with decompensated cirrhosis and those with ACLF. Of 43 selected miRNAs examined for differences among groups, 10 were differentially expressed according to disease progression. Moreover, 20 circulating miRNAs were correlated with model for end-stage liver disease and Child-Pugh scores. Notably, 11 dysregulated miRNAs were associated with kidney or liver failure, encephalopathy, bacterial infection, and poor outcomes. The most severely dysregulated miRNAs (i.e. miR-146a-5p, miR-26a-5p, and miR-191-5p) were further evaluated in portal and hepatic vein blood and liver tissue, but showed no differences. However, PBMCs from patients with cirrhosis showed significant downregulation of miR-26 and miR-146a, suggesting a extrahepatic origin of some circulating miRNAs. Conclusions: This study is a repository of circulating miRNA data following cirrhosis progression and ACLF. Circulating miRNAs were profoundly dysregulated during the progression of chronic liver disease, were associated with failure of several organs and could have prognostic utility. Lay summary: Circulating miRNAs are small molecules in the blood that can be used to identify or predict a clinical condition. Our study aimed to identify miRNAs for use as biomarkers in patients with cirrhosis or acute-on-chronic liver failure. Several miRNAs were found to be dysregulated during the progression of disease, and some were also related to organ failure and disease-related outcomes.

Original languageEnglish
Article number100233
JournalJHEP Reports
Volume3
Issue number2
Number of pages12
ISSN2589-5559
DOIs
Publication statusPublished - Apr 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

Keywords

  • Biomarkers
  • Chronic liver disease
  • Liver decompensation
  • Non-coding RNAs

Fingerprint

Dive into the research topics of 'Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure'. Together they form a unique fingerprint.

Cite this